RS66754B1 - Sastav koji sadrži roginolisib i dozni režim za tretman raka ili inflamatorne ili autoimune bolesti - Google Patents
Sastav koji sadrži roginolisib i dozni režim za tretman raka ili inflamatorne ili autoimune bolestiInfo
- Publication number
- RS66754B1 RS66754B1 RS20250390A RSP20250390A RS66754B1 RS 66754 B1 RS66754 B1 RS 66754B1 RS 20250390 A RS20250390 A RS 20250390A RS P20250390 A RSP20250390 A RS P20250390A RS 66754 B1 RS66754 B1 RS 66754B1
- Authority
- RS
- Serbia
- Prior art keywords
- compound
- cancer
- salt
- treatment
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2104416.9A GB202104416D0 (en) | 2021-03-29 | 2021-03-29 | Treatment reginmens |
| GBGB2117511.2A GB202117511D0 (en) | 2021-12-03 | 2021-12-03 | Treatment regimens |
| EP22719266.3A EP4313058B1 (en) | 2021-03-29 | 2022-03-29 | Composition comprising roginolisib and dosage regime for treating cancer or an inflammatory or autoimmune disease |
| PCT/EP2022/058283 WO2022207646A1 (en) | 2021-03-29 | 2022-03-29 | A pi3k-delta inhibitor for use in treatment regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS66754B1 true RS66754B1 (sr) | 2025-05-30 |
Family
ID=81388915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20250390A RS66754B1 (sr) | 2021-03-29 | 2022-03-29 | Sastav koji sadrži roginolisib i dozni režim za tretman raka ili inflamatorne ili autoimune bolesti |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12605389B2 (https=) |
| EP (1) | EP4313058B1 (https=) |
| JP (1) | JP7839803B2 (https=) |
| AU (1) | AU2022251843B2 (https=) |
| CA (1) | CA3212731A1 (https=) |
| DK (1) | DK4313058T3 (https=) |
| ES (1) | ES3031295T3 (https=) |
| FI (1) | FI4313058T3 (https=) |
| HR (1) | HRP20250516T1 (https=) |
| HU (1) | HUE071610T2 (https=) |
| LT (1) | LT4313058T (https=) |
| MX (1) | MX2023011442A (https=) |
| PL (1) | PL4313058T3 (https=) |
| PT (1) | PT4313058T (https=) |
| RS (1) | RS66754B1 (https=) |
| SI (1) | SI4313058T1 (https=) |
| WO (1) | WO2022207646A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026510567A (ja) * | 2023-03-03 | 2026-04-08 | アイオンクチュラ・ソシエテ・アノニム | 血液悪性腫瘍の治療におけるロギノリシブ及びｂｃｌ－２阻害剤の組み合わせ |
| AU2024231699A1 (en) * | 2023-03-03 | 2025-09-11 | Ionctura Sa | Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201290305A1 (ru) | 2009-11-13 | 2012-12-28 | Мерк Сероно С.А. | Производные трициклического пиразоламина |
| WO2014121901A1 (en) | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Polymorphic forms |
| US9986723B2 (en) | 2014-10-22 | 2018-06-05 | The Board Of Regents Of The University Of Texas System | Screen and use of therapeutics for pancreatic ductal adenocarcinoma |
| GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
| EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
-
2022
- 2022-03-29 WO PCT/EP2022/058283 patent/WO2022207646A1/en not_active Ceased
- 2022-03-29 CA CA3212731A patent/CA3212731A1/en active Pending
- 2022-03-29 AU AU2022251843A patent/AU2022251843B2/en active Active
- 2022-03-29 MX MX2023011442A patent/MX2023011442A/es unknown
- 2022-03-29 HR HRP20250516TT patent/HRP20250516T1/hr unknown
- 2022-03-29 PT PT227192663T patent/PT4313058T/pt unknown
- 2022-03-29 EP EP22719266.3A patent/EP4313058B1/en active Active
- 2022-03-29 DK DK22719266.3T patent/DK4313058T3/da active
- 2022-03-29 HU HUE22719266A patent/HUE071610T2/hu unknown
- 2022-03-29 SI SI202230137T patent/SI4313058T1/sl unknown
- 2022-03-29 FI FIEP22719266.3T patent/FI4313058T3/fi active
- 2022-03-29 PL PL22719266.3T patent/PL4313058T3/pl unknown
- 2022-03-29 LT LTEPPCT/EP2022/058283T patent/LT4313058T/lt unknown
- 2022-03-29 ES ES22719266T patent/ES3031295T3/es active Active
- 2022-03-29 JP JP2023560623A patent/JP7839803B2/ja active Active
- 2022-03-29 US US18/271,196 patent/US12605389B2/en active Active
- 2022-03-29 RS RS20250390A patent/RS66754B1/sr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT4313058T (pt) | 2025-06-02 |
| AU2022251843A1 (en) | 2023-10-05 |
| LT4313058T (lt) | 2025-05-26 |
| US20240058351A1 (en) | 2024-02-22 |
| WO2022207646A1 (en) | 2022-10-06 |
| JP2024518685A (ja) | 2024-05-02 |
| US12605389B2 (en) | 2026-04-21 |
| PL4313058T3 (pl) | 2025-06-23 |
| AU2022251843B2 (en) | 2026-04-09 |
| HUE071610T2 (hu) | 2025-09-28 |
| EP4313058A1 (en) | 2024-02-07 |
| ES3031295T3 (en) | 2025-07-07 |
| CA3212731A1 (en) | 2022-10-06 |
| SI4313058T1 (sl) | 2025-07-31 |
| EP4313058B1 (en) | 2025-03-05 |
| FI4313058T3 (fi) | 2025-04-30 |
| MX2023011442A (es) | 2023-10-18 |
| JP7839803B2 (ja) | 2026-04-02 |
| HRP20250516T1 (hr) | 2025-06-20 |
| DK4313058T3 (da) | 2025-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8513266B2 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | |
| US9364476B2 (en) | Methods of treating a Bruton's Tyrosine Kinase disease or disorder | |
| US10391092B2 (en) | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy | |
| US20170189409A1 (en) | Medical use | |
| JP2012508775A (ja) | 血液学的な悪性疾患のための療法 | |
| JP2013500257A (ja) | Ｐｉ３ｋインヒビターでの肝障害の処置 | |
| EP3695839A1 (en) | Therapeutic agent for solid cancers, which contains axl inhibitor as active ingredient | |
| JP6357292B2 (ja) | Ｃｎｋｓｒ１を阻害するための方法及び組成物 | |
| KR20160126984A (ko) | 아필리모드 조성물 및 이를 사용하기 위한 방법 | |
| CN110636844A (zh) | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 | |
| RS66754B1 (sr) | Sastav koji sadrži roginolisib i dozni režim za tretman raka ili inflamatorne ili autoimune bolesti | |
| Xie et al. | Puquitinib, a novel orally available PI 3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia | |
| CA2831932A1 (en) | Combinations of akt and mek inhibitor compounds, and methods of use | |
| US20140142129A1 (en) | Methods of treating a disease or disorder associated with bruton's tyrosine kinase | |
| TW202021593A (zh) | 復發性濾泡淋巴瘤之治療 | |
| EP3125935B1 (en) | Combinations of cancer therapeutics | |
| CN117042778A (zh) | 用于治疗方案的PI3K-δ抑制剂 | |
| TW202133853A (zh) | 包含PKC-β抑制劑的組合物及其製備方法 | |
| TW202002952A (zh) | 用於治療胰臟癌之abbv-621與抗癌劑之組合 | |
| KR20180112066A (ko) | 피롤로-융합된 6-원의 헤테로시클릭 화합물을 포함하는 약학적 조성물 | |
| JP7049006B2 (ja) | 細胞における自食作用抑制用組成物、及びこれを含む腫瘍性疾患の予防または治療用、あるいは抗がん剤の耐性抑制用薬学的組成物 | |
| TW202313042A (zh) | 包含PKCβ抑制劑之組合物及其製備方法 | |
| Iabkriman et al. | PI3K inhibitors in medical oncology: Update on an emerging treatment modality | |
| WO2025036856A1 (en) | Pharmaceutical formulation comprising a coated tablet | |
| WO2014193589A1 (en) | Cancer treatment method |